Tirosint Cost in Massachusetts 2026: Cash Price, Insurance, Medicaid, and Cheaper Alternatives

What Is Tirosint and Why Does It Cost More Than Generic Levothyroxine?

Tirosint is a brand-name formulation of levothyroxine sodium delivered in a soft gel capsule or a liquid solution (Tirosint-SOL), manufactured by IBSA Institut Biochimique SA. Its price sits above standard levothyroxine tablets because the formulation contains no dye, no gluten, no lactose, and no acacia, and it dissolves in a water-based medium rather than a compressed tablet matrix.

That difference matters clinically. Vita et al. (2014, N=45) demonstrated that levothyroxine absorption from the liquid formulation was significantly higher than from standard tablets in patients with lactose intolerance and other gastrointestinal conditions, with TSH normalization achieved faster in the liquid group (1). The FDA-approved label for Tirosint documents bioavailability between 80 and 99 percent, which exceeds the 64-percent floor set for standard tablet formulations (2).

Standard levothyroxine tablets cost $4-$10 per month at most Massachusetts pharmacies under generic pricing. Tirosint's cash price of approximately $230 per month reflects both the proprietary formulation and the absence of an AB-rated generic equivalent in the gel-capsule or liquid category. No generic soft gel cap has received FDA approval as of mid-2025 (2).

Thyroid hormone replacement is among the most commonly prescribed drug classes in the United States. The American Thyroid Association estimates that hypothyroidism affects approximately 4.6 percent of the U.S. population age 12 and older, and levothyroxine consistently ranks among the top three most-dispensed drugs nationally (3). In Massachusetts, that translates to hundreds of thousands of patients on some form of levothyroxine, most of whom pay far less than $230 monthly because they take tablets.

Exact Tirosint Cash Price at Massachusetts Pharmacies in 2026

The average cash-pay price for Tirosint at Massachusetts retail pharmacies in 2026 is $230 per month for a 30-capsule supply of the most common strengths (75 mcg, 88 mcg, 100 mcg). Prices vary modestly by chain and location.

CVS, Walgreens, and Rite Aid locations across Boston, Worcester, Springfield, and other Massachusetts cities typically price Tirosint within a $215-$245 range without any discount card. Independent pharmacies may quote slightly higher or lower depending on their wholesaler contract. Mail-order pharmacies affiliated with major pharmacy benefit managers (PBMs) tend to price similarly on cash pay but often offer better out-of-pocket costs for insured patients.

GoodRx and similar coupon aggregators sometimes list Tirosint discounts in the $180-$210 range at specific Massachusetts ZIP codes, though these coupons are not accepted at all locations and cannot be combined with insurance (4). A 2022 analysis published in JAMA Internal Medicine found that pharmacy discount cards reduce out-of-pocket drug costs by a median of 33 percent for brand-name drugs without generic equivalents, though savings vary significantly by drug class (5).

Patients who pay full cash price for 12 months of Tirosint spend approximately $2,760 per year, compared with roughly $60-$120 annually for generic levothyroxine tablets at the same pharmacies. That $2,600+ annual gap is the central cost question this article addresses.

Massachusetts Medicaid (MassHealth) Coverage for Tirosint

MassHealth covers Tirosint with a prior authorization (PA) requirement for hypothyroidism in patients with documented malabsorption conditions or other clinical indications where standard tablet absorption is unreliable. "Covered with PA" means the prescribing clinician must submit clinical documentation before MassHealth will reimburse the drug.

The MassHealth Drug List (formerly the Preferred Drug List) places Tirosint in a non-preferred brand tier. Prior authorization criteria typically require (6):

• A confirmed diagnosis of hypothyroidism (ICD-10 E03.9 or a specific variant)
• Documentation of a clinical reason standard levothyroxine tablets are insufficient (e.g., celiac disease, post-bariatric surgery malabsorption, documented TSH instability on tablets)
• A prescriber attestation that a trial of standard generic levothyroxine was inadequate or contraindicated

Once the PA is approved, MassHealth enrollees pay a nominal copay, often $3.65 for brand drugs under the Standard Plan. Members enrolled in a MassHealth managed care entity (MCE) such as Tufts Health Together or Boston Medical Center HealthNet Plan may have slightly different PA criteria, so verifying with the specific MCE formulary is advisable.

The Centers for Medicare and Medicaid Services notes that states must cover medically necessary drugs in certain protected classes, though thyroid hormones do not fall under the six protected CMS classes, which means states retain more flexibility in their coverage restrictions (6). Patients denied PA have the right to appeal; the MassHealth appeal process typically requires a response within 72 hours for standard requests or 24 hours for urgent clinical situations.

For patients on Medicare Part D, Tirosint coverage depends on the specific plan formulary. A 2023 CMS analysis found that about 62 percent of Part D standalone plans placed brand-name thyroid medications in tiers requiring coinsurance rather than fixed copays, which can make out-of-pocket costs unpredictable (7).

Which Commercial Insurance Plans Cover Tirosint in Massachusetts?

Most major commercial plans operating in Massachusetts, including Blue Cross Blue Shield of Massachusetts, Harvard Pilgrim Health Care, Tufts Health Plan, and Aetna, place Tirosint on a non-preferred brand tier. Tier placement directly drives what patients pay.

On a non-preferred brand tier, a typical Massachusetts commercial plan charges 40-50 percent coinsurance or a fixed copay of $60-$120 per 30-day fill, after the deductible is met. Before the deductible is satisfied, patients pay the full negotiated rate, which may still be lower than cash price due to the PBM's contracted rate with IBSA (8).

A 2021 analysis in the New England Journal of Medicine found that the average patient with commercial insurance paid 18 percent of the list price for non-preferred brand drugs after accounting for manufacturer rebates passed to the PBM, though those rebates rarely flow directly to the patient at the point of sale (8). That dynamic is particularly relevant for Tirosint, where the IBSA savings card (see below) can close the gap for commercially insured patients.

Patients with high-deductible health plans (HDHPs), which are common among Massachusetts residents who purchase coverage through the Massachusetts Health Connector, may face full cash exposure for Tirosint until they meet their annual deductible, which averaged $1,650 for single coverage in employer-sponsored plans nationally in 2023 (9). Step therapy requirements are increasingly common; some Massachusetts plans require a documented trial of standard levothyroxine tablets before approving Tirosint at a preferred tier.

How the IBSA Savings Card Works in Massachusetts

IBSA, Tirosint's manufacturer, offers a savings card program that allows eligible commercially insured patients to pay as little as $25 per fill, with a maximum annual benefit that varies by program year. The card does not apply to government-funded insurance, meaning MassHealth, Medicare Part D, Medicaid managed care, or any federal or state employee plan funded with government dollars is excluded.

To use the savings card in Massachusetts:

1. Confirm the patient has commercial insurance (not Medicare, Medicaid, or a government-funded plan).
2. Download or print the IBSA savings card from the manufacturer website or request it through the prescribing clinician.
3. Present the card at any participating Massachusetts retail pharmacy alongside the insurance card. The card acts as a secondary payer, covering the difference between the insurance copay and $25, up to the program cap.

The annual maximum benefit under past IBSA card programs has been approximately $2,000-$3,000 per patient, which is sufficient to cover most commercially insured patients' out-of-pocket costs for a full year at non-preferred tier copays. Program terms reset annually, so patients should re-enroll each January (10).

A 2021 study in Health Affairs found that manufacturer copay assistance cards increase brand-drug adherence by up to 22 percent relative to patients without cards, but critics note they insulate patients from the true cost of branded drugs and may increase overall system spending (10). For an individual Massachusetts patient facing a $120 monthly copay, the card is a direct financial tool regardless of that broader debate.

Compounded Levothyroxine Liquid/Gel Caps in Massachusetts: Legality and Cost

Compounded levothyroxine in liquid or gel-capsule form is legal in Massachusetts through state-licensed 503A compounding pharmacies. A 503A pharmacy compounds medications for individual patients pursuant to a valid prescription from a licensed prescriber. Massachusetts pharmacies must hold a current license from the Massachusetts Board of Registration in Pharmacy, and compounded levothyroxine must meet USP standards for potency and sterility where applicable (11).

The cost difference is significant. Compounded levothyroxine liquid or gel caps from a 503A Massachusetts pharmacy typically cost $0-$30 per month for patients whose insurance covers compounded preparations, and $20-$60 per month cash pay, compared with $230 for branded Tirosint. Some Massachusetts commercial plans cover 503A-compounded drugs when the prescriber documents medical necessity and no commercially available product meets the patient's clinical need.

The FDA does not approve compounded drugs individually; each batch is prepared for a specific patient per prescription. The FDA's guidance on 503A compounding states that pharmacies may compound levothyroxine "if a valid prescription exists for an identified individual patient and the compounded preparation is not essentially a copy of an approved commercially available product" (11). Because Tirosint is commercially available, some compounding pharmacies require the prescriber to document a specific clinical reason the branded product is inadequate, such as an allergy to an excipient in Tirosint or a dose strength that is not commercially produced.

Potency accuracy in compounded thyroid preparations has been a documented concern. A 2013 study published in Thyroid found that compounded thyroid preparations varied by as much as plus or minus 30 percent from labeled potency in some samples, compared with the FDA's allowable range of 90-110 percent for approved levothyroxine products (12). Patients who switch to compounded levothyroxine should recheck TSH levels 6-8 weeks after the transition to confirm adequate dosing, per standard American Thyroid Association monitoring guidance (13).

Can Massachusetts Patients Get Tirosint Through Telehealth?

Yes. Telehealth prescribing of Tirosint is permitted in Massachusetts for established and new patients, provided the prescribing clinician holds a valid Massachusetts medical license and conducts a clinically appropriate evaluation. Massachusetts joined the Interstate Medical Licensure Compact (IMLC), which allows physicians licensed in other compact states to obtain expedited Massachusetts licensure, broadening the pool of clinicians who can prescribe remotely to Massachusetts residents (14).

The Massachusetts telehealth law (M.G.L. c. 175, Section 47BB) requires that telehealth services meet the same standard of care as in-person visits. A clinician prescribing Tirosint via video visit must review prior TSH results, assess the indication for the gel-capsule formulation rather than tablets, and document the clinical rationale. Audio-only visits without video are permitted for established patients under current Massachusetts rules but may face renewed scrutiny as post-pandemic telehealth waivers expire (15).

HealthRX clinicians licensed in Massachusetts can evaluate patients for Tirosint appropriateness during a video consultation. The visit typically involves reviewing recent thyroid function tests (TSH, free T4), current levothyroxine dosing history, and any gastrointestinal conditions that affect tablet absorption. A prescription can be transmitted electronically to the Massachusetts pharmacy of the patient's choice, including mail-order pharmacies, at the close of the visit.

The Cheapest Way to Get Tirosint in Massachusetts: A Decision Path

The lowest-cost path depends on insurance status, clinical indication, and tolerance for the compounding option. Here is a direct breakdown.

Commercially insured patients: Use the IBSA savings card alongside existing commercial coverage. Expected out-of-pocket cost: $25 per fill or roughly $300 per year, well below cash price.

MassHealth/Medicaid patients: Pursue prior authorization with documentation of malabsorption or TSH instability on standard tablets. If PA is approved, copay is approximately $3.65 per fill under Standard MassHealth, totaling less than $44 per year. If PA is denied, file an appeal with supporting clinical records.

Medicare Part D patients: Review the specific Part D plan formulary. If Tirosint is on the formulary, use any available manufacturer patient assistance program (noting the savings card excludes Part D). If the plan does not cover Tirosint, the prescriber can request a formulary exception. The IBSA Patient Assistance Program (PAP) may cover uninsured or underinsured patients who meet income criteria; applications are processed through the prescriber's office (16).

Uninsured or underinsured patients: The compounded levothyroxine liquid/gel cap from a Massachusetts 503A pharmacy is the least expensive option, typically $20-$60/month cash pay. A 90-day supply often reduces per-day cost further. Confirm potency accuracy with a TSH recheck at 6-8 weeks.

Patients with documented medical necessity and insurance that covers compounded drugs: Submit a prior authorization for the compounded preparation with the prescriber's letter documenting why Tirosint or standard tablets are clinically insufficient. Some Blue Cross Blue Shield of Massachusetts plans and Harvard Pilgrim plans have covered 503A compounded levothyroxine under specialty drug benefits when documentation is thorough.

Monitoring Requirements and Dose Adjustment After Starting Tirosint

Starting or switching to Tirosint in Massachusetts requires the same monitoring framework as any levothyroxine formulation. The American Thyroid Association 2014 guidelines recommend checking TSH 6-8 weeks after initiating therapy or after any dose change, with a target TSH between 0.4 and 4.0 mIU/L for most adult patients (13).

Patients switching from standard levothyroxine tablets to Tirosint gel caps may require a dose adjustment, because the higher bioavailability of the gel cap can produce a lower TSH (higher free T4) at the same mcg dose. Vita et al. (2014) reported that patients transitioned from tablets to liquid levothyroxine achieved equivalent TSH suppression at a mean dose approximately 11 percent lower than their prior tablet dose (1). Prescribers should consider initiating Tirosint at 90-95 percent of the patient's prior tablet dose and rechecking TSH at 6 weeks (17).

Tirosint should be taken on an empty stomach, 30-60 minutes before the first meal, consistent with all levothyroxine formulations. Calcium carbonate, ferrous sulfate, and antacids containing aluminum hydroxide can each reduce levothyroxine absorption by 30-40 percent if taken within four hours of the dose (18). Patients who switched to Tirosint specifically for absorption reasons should still observe these timing rules; the gel cap improves absorption relative to tablets but does not eliminate drug-interaction considerations.

TSH testing is covered by virtually all Massachusetts commercial insurance plans and by MassHealth without a copay as a preventive or diagnostic lab service. Quest Diagnostics and LabCorp both have Massachusetts draw sites with rapid turnaround, typically 24-48 hours for TSH results, which allows prescribers to adjust doses efficiently via telehealth follow-up without requiring an in-person visit.

Clinical Rationale: When Tirosint Is Medically Justified Over Generic Tablets

Generic levothyroxine tablets are therapeutically appropriate for the majority of hypothyroid patients. Tirosint's clinical advantage is specifically documented in patients with conditions that impair tablet absorption. Published evidence supports the gel-cap or liquid formulation in:

• Celiac disease and gluten-sensitive enteropathy: A controlled study (N=34) in the Journal of Clinical Endocrinology and Metabolism found that patients with celiac disease achieved significantly better TSH control on levothyroxine liquid than on tablets, with 85 percent reaching target TSH on liquid versus 49 percent on tablets over a 12-month period (19).
• Post-bariatric surgery malabsorption: Roux-en-Y gastric bypass alters the proximal small bowel where levothyroxine is primarily absorbed. A 2017 review in Thyroid reported that post-bariatric patients required a median 30 percent higher levothyroxine dose to maintain the same TSH as pre-surgery, and liquid formulations produced more stable TSH levels than tablets in this population (17).
• Coffee and proton-pump inhibitor users: A study published in Thyroid (N=51) found that patients who took levothyroxine tablets with coffee experienced a 29 percent reduction in absorption, whereas the liquid formulation showed no statistically significant absorption change under the same conditions (20).
• Lactose intolerance: Standard levothyroxine tablets contain lactose as an excipient. Vita et al. (2014) specifically demonstrated absorption benefits in lactose-intolerant patients (1).

The American Association of Clinical Endocrinology (AACE) position statement on levothyroxine therapy notes: "Patients with persistent TSH instability despite optimal tablet-form levothyroxine compliance should be evaluated for malabsorption conditions, and liquid or soft-gel formulations represent a validated clinical alternative" (21). That statement directly supports the PA criteria MassHealth uses for Tirosint coverage.

For Massachusetts patients who are TSH-stable on generic tablets with no gastrointestinal conditions, switching to Tirosint for cost reasons alone does not carry clinical support. The $230 monthly cash price is not justified when a $4-$10 generic tablet produces the same clinical outcome.